Loading
Obesity and Cardiovascular Risk / Oral BGE-102 / Oral Placebo Matching BGE-102 · Phase 2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registration for BGE-102, an oral agent being tested in obese participants with cardiovascular risk factors. The trial is actively recruiting and has not yet reported results; it is designed to evaluate pharmacodynamics and safety using hsCRP change as the primary surrogate endpoint at 12 weeks.
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity and Cardiovascular Risk; age from 18 Years. Intervention: Arm A: BGE-102 Dose A; Arm B: BGE-102 Dose B; Arm C: BGE-102 Dose C. Compared with: Arm D: Dose D — Placebo Comparator. n = 160. 17 sites: United States, Puerto Rico.
This is a Phase 2 clinical trial registration for BGE-102, an oral agent being tested in obese participants with cardiovascular risk factors. The trial is actively recruiting and has not yet reported results; it is designed to evaluate pharmacodynamics and safety using hsCRP change as the primary surrogate endpoint at 12 weeks.
No efficacy or safety data are available from this registration
Results from this trial may inform dose selection and mechanistic plausibility for BGE-102 in obesity and cardiovascular risk; however, surrogate biomarker changes do not directly establish clinical benefit. Clinical utility will depend on future hard endpoint trials.
This is a Phase 2 trial still recruiting that has not yet reported results; it measures a surrogate inflammatory biomarker (hsCRP) rather than clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Results from this trial may inform dose selection and mechanistic plausibility for BGE-102 in obesity and cardiovascular risk; however, surrogate biomarker changes do not directly establish clinical benefit. Clinical utility will depend on future hard endpoint trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07656727). This is a study registration, not published results. Lead sponsor: BioAge Labs, Inc.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 160 participants (ESTIMATED). Conditions: Obesity and Cardiovascular Risk. Interventions: DRUG: Oral BGE-102; DRUG: Oral Placebo Matching BGE-102. Primary outcome measures: Percent change in hsCRP (Dose A) , Week 12; Percent change in hsCRP (Dose B) , Week 12; Percent change in hsCRP (Dose C) , Week 12. Brief summary: The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.